'On standalone basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Sanofi India has declined 9.27% to Rs 475.40 crore. Operating profit margin has jumped from 22.84% to 28.23%, leading to 12.11% rise in operating profit to Rs 134.20 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.66% to 9.54%. Purchase of finished goods cost rose from 36.11% to 48.30%. Employee cost decreased from 10.14% to 7.50%. Other expenses fell from 15.67% to 10.63%.
Other income up 113.04% to Rs 4.9 crore. PBIDT rose 14.02% to Rs 139.1 crore. Provision for interest remained nil.
PBDT rose 14.06% to Rs 138.7 crore. Provision for depreciation rose 1.11% to Rs 9.1 crore.
Profit before tax grew 15.10% to Rs 129.60 crore. &nb...
Pleaselogin & subscribe to view the full report.
More Reports
|
|